Find clinical trials for Kidney Disease in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases

Chronic Renal Insufficiency

Chronic Kidney Failure

Renal Insufficiency

IGA Glomerulonephritis

Renal Cell Carcinoma

Carcinoma

Kidney Disease trials near London, England, GBR:

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka

London, United Kingdom and 17 other locations

A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys...

Enrolling

Chronic Kidney Diseases

Type 2 Diabetes Mellitus

Biological: Renal Autologous Cell Therapy (REACT)

Procedure: Sham Comparator

Phase 3

Prokidney

London, United Kingdom and 45 other locations

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling

Chronic Kidney Disease With High Proteinuria

Drug: Dapagliflozin

Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca

London, United Kingdom and 338 other locations

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney ...

Enrolling

Autosomal Recessive Polycystic Kidney (ARPKD)

Drug: Tolvaptan Suspension

Drug: Tolvaptan Tablets

Phase 3

Otsuka

London, United Kingdom and 18 other locations

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease (MIRO-CKD)

compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...

Enrolling

Chronic Kidney Disease

Drug: Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin

Drug: Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg

Phase 2

AstraZeneca

London, United Kingdom and 112 other locations

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...

Active, not recruiting

Non-diabetic Chronic Kidney Disease

Drug: Finerenone (BAY94-8862)

Drug: Placebo

Phase 3

Bayer

London, United Kingdom and 312 other locations

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling

Proteinuric Kidney Disease

Drug: Placebo

Drug: VX-147

Phase 2, Phase 3

Vertex Pharmaceuticals

London, United Kingdom and 243 other locations

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes (FINE-ONE)

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys...

Enrolling

Chronic Kidney Disease

Type 1 Diabetes Mellitus

Other: Placebo

Drug: Finerenone

Phase 3

Bayer

London, United Kingdom and 80 other locations

Locations recently updated

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling

Chronic Kidney Disease

Cardiac Disease

Drug: Placebo

Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals

London, United Kingdom and 178 other locations

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (FIONA OLE)

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling

Chronic Kidney Disease

Proteinuria

Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer

London, United Kingdom and 146 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Kidney Disease in .css-epvm6{white-space:nowrap;}London, England

Related conditions:

Kidney Disease trials near London, England, GBR:

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease (MIRO-CKD)

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes (FINE-ONE)

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (FIONA OLE)

Find clinical trials for Kidney Disease in London, England